Interferon-α2b/ribavirin (REBETRON®) treatment for chronic hepatitis C -: Population pharmacokinetics and pharmacodynamics of ribavirin.

被引：0
|
作者：
Glue, P [1 ]
Jen, F [1 ]
Gupta, SK [1 ]
Lau, G [1 ]
机构：
[1] Schering Plough Corp, Res Inst, Kenilworth, NJ 07033 USA
来源：
HEPATOLOGY | 1999年 / 30卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
119
引用
收藏
页码：190A / 190A
页数：1
相关论文
共 50 条
  • [21] Interferon-α-2b/pegylated interferon and ribavirin treatment in renal disease with renal insufficiency and chronic hepatitis C infection
    Bruchfeld, A
    Lindahl, K
    Schvarcz, R
    Ståhle, L
    ANTIVIRAL THERAPY, 2002, 7 (04) : L127 - L127
  • [22] Pegylated Interferon-α2a and Ribavirin versus Pegylated Interferon-α2b and Ribavirin in Chronic Hepatitis CA Meta-Analysis
    Nicolas Flori
    Natalie Funakoshi
    Yohan Duny
    Jean-Christophe Valats
    Michael Bismuth
    Dimitri Christophorou
    Jean-Pierre Daurès
    Pierre Blanc
    Drugs, 2013, 73 : 263 - 277
  • [23] Pegylated interferon α-2b, ribavirin and amantadine for chronic hepatitis C
    Younossi, ZM
    McCullough, A
    Barnes, D
    Post, A
    Ong, J
    O'Shea, R
    Martin, LM
    Bringman, D
    Farmer, D
    Levinthal, G
    Mullen, KD
    Carey, WD
    Tavill, AS
    Ferguson, R
    Gramlich, T
    DIGESTIVE DISEASES AND SCIENCES, 2005, 50 (05) : 970 - 975
  • [24] Pegylated Interferon α-2b, Ribavirin and Amantadine for Chronic Hepatitis C
    Zobair M. Younossi
    Arthur C. McCullough
    David S. Barnes
    Anthony Post
    Janus P. Ong
    Robert O’shea
    Lisa M. Martin
    Diane Bringman
    Denise Farmer
    Gavin Levinthal
    Kevin D. Mullen
    William D. Carey
    Anthony S. Tavill
    Roy Ferguson
    Terry Gramlich
    Digestive Diseases and Sciences, 2005, 50 : 970 - 975
  • [25] Durability of sustained virologic response in patients with chronic hepatitis C after treatment with interferon α-2b alone or in combination with ribavirin.
    McHutchison, JG
    Davis, GL
    Esteban-Mur, R
    Poynard, T
    Ling, MH
    Garaud, JJ
    Albrecht, J
    HEPATOLOGY, 2001, 34 (04) : 244A - 244A
  • [26] Interferon-α2b induction treatment with or without ribavirin in chronic hepatitis C -: A multicenter, randomized, controlled trial
    Senturk, H
    Ersoz, G
    Ozaras, R
    Kaymakoglu, S
    Bozkaya, H
    Akdogan, M
    Mert, A
    Bozdayi, M
    Tabak, F
    Yenice, N
    Ozbay, G
    DIGESTIVE DISEASES AND SCIENCES, 2003, 48 (06) : 1124 - 1129
  • [27] Interferon-α-2b plus ribavirin -: A review of its use in the management of chronic hepatitis C
    Scott, LJ
    Perry, CM
    DRUGS, 2002, 62 (03) : 507 - 556
  • [28] Interferon-α2b Induction Treatment with or Without Ribavirin in Chronic Hepatitis C: A Multicenter, Randomized, Controlled Trial
    Hakan Senturk
    Galip Ersoz
    Resat Ozaras
    Sabahattin Kaymakoglu
    Hakan Bozkaya
    Meral Akdogan
    Ali Mert
    Mithat Bozdayi
    Fehmi Tabak
    Necati Yenice
    Gulsen Ozbay
    Digestive Diseases and Sciences, 2003, 48 : 1124 - 1129
  • [29] Cost effectiveness of interferon α2b combined with ribavirin for the treatment of chronic hepatitis C
    Younossi, ZM
    Singer, ME
    McHutchison, JG
    Shermock, KM
    HEPATOLOGY, 1999, 30 (05) : 1318 - 1324
  • [30] Efficacy and Tolerability of Pegylated Interferon-α2a plus Ribavirin versus Pegylated Interferon-α2b plus Ribavirin in Treatment-Naive Chronic Hepatitis C Patients
    Lee, Seok
    Kim, In Hee
    Kim, Seong Hun
    Kim, Sang Wook
    Lee, Seung Ok
    Lee, Soo Teik
    Kim, Dae Ghon
    Lee, Chang Seop
    Choi, Chang Soo
    Cho, Eun Young
    Kim, Haak Cheoul
    INTERVIROLOGY, 2010, 53 (03) : 146 - 153
12345